Conclusion.
The incidence of empyema in Scottish children initially rose in children aged 1 to 9 years after the introduction of routine conjugate pneumococcal vaccination however empyema incidence has fallen since 2010 when the 13-valent pneumococcal vaccine was introduced.
INTRODUCTION
Empyema is a serious complication of pneumonia in children. A number of studies reported an increasing incidence of paediatric empyema during the 1990s and early 2000s [1] [2] [3] [4] [5] [6] . Streptococcus pneumoniae (pneumococcus) is a common cause of pneumonia and the most common pathogen isolated in empyema 7, 8 but our previous data suggested that changes in the epidemiology of empyema occurred at a time when pneumonia incidence was static 1 . One explanation for the increasing incidence of empyema might be changes in pneumococcal virulence or serotype distribution.
Routine vaccination beginning in infancy with a 7 valent pneumococcal conjugate vaccine (PCV-7)
containing antigen against serotypes 4, 6B, 9V, 14, 18C, 19F and 23F was introduced in the USA in 2000
and subsequently into the UK paediatric schedule in 2006. In the UK, this programme appears to have been effective in reducing the frequency of hospital admissions for pneumonia 8, 9 . In April 2010, PCV-7
was superseded by a 13-valent vaccine (PCV-13) providing coverage for six additional serotypes (1, 3, 5, 6A, 7F and 19A); these serotypes are responsible for a significant proportion of invasive pneumococcal disease in UK children 2 and the PCV-13 might therefore be expected to lead to a reduction in the incidence of empyema.
We have previously reported data on the incidence of empyema for the childhood population of 
Analysis
Incidence rate for admission was given per million children in the population as previously There were insufficient empyema data available to perform vaccine specific analyses. Similar techniques have been used to assess the impact of vaccination on pneumonia and empyema. 11, 12 Standard statistical software was used (SPSS version 20.0.0 and R version 3.0.1 -nLME & epiR packages) and significance was assumed when p<0.05. ; age group specific differences were seen, with an increase focussed in the 1-4 and 5-9 years age groups (data not presented). Admission incidence for empyema across all age groups combined, increased in the PCV-7 period (incidence rate ratio, IRR, 2.14 [95% CI and 4122).
RESULTS

Between
DISCUSSION
The incidence of empyema in children was still rising abruptly in Scotland in 2005 when we published our previous study 1 and the present study demonstrates that this rise continued after introduction of routine pneumococcal vaccination in 2006 but fell after 13-valent vaccination was introduced in 2010.
Where serotype data were available for the PCV-7 vaccination era, all cases were infected with non PCV-7 serotypes suggesting that by extrapolation, the 13-valent conjugate vaccines may be effective in preventing invasive disease from the serotypes covered. Non-vaccine serotypes continue to cause morbidity in the UK as has been previously reported 2, 13 . Empyema incidence now seems to be falling following the introduction of the PCV-13 vaccine (figure 1) but incidence in 2013 remains considerably higher than 2000.
Our results are generally consistent with reports of increasing empyema incidence during the 2000s from the UK and other countries. Two studies from the US 5, 14 have observed rises in empyema incidence of a very similar order as we report here although in the US studies, pneumonia incidence had fallen several years before the reduction seen in our population ( ; here we report a 22% reduction in incident rate ratio after 2010 (table 1) for all children with the largest fall also being seen in infants. The greatest fall might be expected in infants since this age group will all have had the opportunity for vaccination, whereas children born before 2010 will not have received protection of 13-valent vaccination.
There are a number of mechanisms which might explain changing empyema admissions and these include (non-exclusively) changes in referral patterns, pneumonia incidence, exposure to environmental factors (e.g. second hand smoke) and antibiotic prescribing. Changes in admission incidence for croup between 2000 and 2013 do indicate changing drivers for referral to hospital with paediatric respiratory conditions per se but the changes in incidence for croup and empyema were different and we imagine that very few cases of paediatric empyema will be managed in the community. Changes in empyema admissions were different to those of pneumonia, suggesting that the mechanism for the changes in empyema do not directly reflect changes in pneumonia incidence as we have previously observed 1 . We do not believe that increasing empyema admission incidence is secondary to a reduction in threshold for referral or an increase in pneumonia. A further mechanism which might explain changing empyema incidence is "serotype replacement disease" where, following the introduction of a vaccine, non-vaccine serotypes become important pathogens. A recent study from England and Wales following introduction of the heptavalent vaccine concluded that herd immunity was well established providing uptake was good but also found evidence of serotype replacement with non-vaccine organisms 19 . In Alaska, non vaccine type organisms were responsible for a significant rise in invasive pulmonary infections in a small population of Alaskan children 20 and in the UK, there has been a rise in serotype 19A invasive disease since the introduction of the 13 valent conjugate vaccine 2 . What remains to be seen is whether in future, empyema incidence rises again due to infections with Pneumococcal serotypes not included in the 13-valent.
There are a number of limitations to this study which should be considered when interpreting the results. First, we report admission incidence and not the number of children admitted and a single child admitted twice during an empyema illness would count as two admissions and therefore falsely inflate the incidence of empyema, but we believe that this is unlikely to be a significant factor. Secondly, data is likely to be independent of serotype, our serotype results are at best indicative of the actual serotype profile. Finally, although we suggest that there has been a fall in empyema incidence since 2010, our experience is that there may be some delay between admission and notification to ISD and therefore incidence may be underestimated.
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